SIGA Technologies, a New York-based commercial-stage pharmaceutical company, is targeting the health security markets in the United States. The company's primary focus is on TPOXX, an oral antiviral drug that has proven to be effective in treating smallpox caused by variola virus. With a history dating back to 1995, SIGA Technologies has been actively working to combat various health-related issues through technological advancements in the field of medicine.
SIGA's ticker is SIGA
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 51-200 employees working at SIGA
It is siga.com
SIGA is in the Healthcare sector
SIGA is in the Biotechnology industry
The following five companies are SIGA's industry peers: